Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCYC Bicycle Therapeutics	$7.42 +0.1%	$8.20	$6.10 ▼ $28.67	$513.86M	1.46	391,425 shs	346,706 shs
COGT Cogent Biosciences	$7.23 -0.1%	$5.48	$3.72 ▼ $12.61	$823.18M	1.82	1.30 million shs	4.01 million shs
CRMD CorMedix	$13.61 +0.2%	$11.46	$3.61 ▼ $15.38	$923.10M	1.62	1.24 million shs	1.68 million shs
RTTR Ritter Pharmaceuticals	$3.62 -3.2%	$2.99	$0.15 ▼ $1.27	$167.03M	-0.43	14.23 million shs	8,748 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCYC Bicycle Therapeutics	0.00%	-11.35%	-8.40%	-18.28%	-64.24%
COGT Cogent Biosciences	0.00%	+2.12%	+46.06%	+0.98%	-14.94%
CRMD CorMedix	0.00%	-6.52%	+11.01%	+24.75%	+214.32%
RTTR Ritter Pharmaceuticals	-3.21%	-2.50%	-3.75%	+12.39%	+1,835.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCYC Bicycle Therapeutics	3.41 of 5 stars	4.4	1.0	0.0	0.0	2.3	4.2	0.6
COGT Cogent Biosciences	1.7454 of 5 stars	3.4	3.0	0.0	0.0	1.4	0.0	0.6
CRMD CorMedix	1.0421 of 5 stars	2.6	1.0	0.0	0.0	2.7	0.0	0.6
RTTR Ritter Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCYC Bicycle Therapeutics	2.70	Moderate Buy	$25.00	236.93% Upside
COGT Cogent Biosciences	2.75	Moderate Buy	$14.57	101.54% Upside
CRMD CorMedix	3.17	Buy	$15.83	16.34% Upside
RTTR Ritter Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest RTTR, CRMD, COGT, and BCYC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	CRMD CorMedix	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$13.00 ➝ $17.00
6/17/2025	COGT Cogent Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/29/2025	COGT Cogent Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$21.00 ➝ $25.00
5/20/2025	COGT Cogent Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $12.00
5/7/2025	COGT Cogent Biosciences	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$8.00 ➝ $7.00
5/7/2025	CRMD CorMedix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $15.00
5/6/2025	CRMD CorMedix	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
5/5/2025	BCYC Bicycle Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $17.00
5/2/2025	BCYC Bicycle Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$35.00 ➝ $32.00
5/2/2025	BCYC Bicycle Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$17.00 ➝ $14.00
5/2/2025	BCYC Bicycle Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$26.00 ➝ $22.00

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCYC Bicycle Therapeutics	$35.28M	14.56	N/A	N/A	$11.48 per share	0.65
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$1.32 per share	N/A
CRMD CorMedix	$43.47M	21.23	N/A	N/A	$1.40 per share	9.72
RTTR Ritter Pharmaceuticals	N/A	N/A	N/A	N/A	$0.10 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCYC Bicycle Therapeutics	-$169.03M	-$3.14	N/A	N/A	N/A	-790.07%	-25.54%	-21.23%	8/5/2025 (Estimated)
COGT Cogent Biosciences	-$255.86M	-$1.84	N/A	N/A	N/A	N/A	-149.79%	-75.61%	8/5/2025 (Estimated)
CRMD CorMedix	-$17.93M	$0.22	61.87	14.48	N/A	20.81%	22.57%	17.02%	8/13/2025 (Estimated)
RTTR Ritter Pharmaceuticals	-$10.13M	N/A	N/A	∞	N/A	N/A	N/A	-162.05%	N/A

Latest RTTR, CRMD, COGT, and BCYC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2025	Q1 2025	COGT Cogent Biosciences	-$0.56	-$0.52	+$0.04	-$0.52	N/A	N/A
5/6/2025	Q1 2025	CRMD CorMedix	$0.25	$0.30	+$0.05	$0.30	$38.90 million	$39.08 million
5/1/2025	Q1 2025	BCYC Bicycle Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$8.67 million	$9.98 million
3/25/2025	Q4 2024	CRMD CorMedix	$0.17	$0.22	+$0.05	$0.22	$27.46 million	$30.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
RTTR Ritter Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCYC Bicycle Therapeutics	N/A	14.86	14.86
COGT Cogent Biosciences	N/A	5.13	5.13
CRMD CorMedix	N/A	4.21	3.99
RTTR Ritter Pharmaceuticals	N/A	3.67	3.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCYC Bicycle Therapeutics	86.15%
COGT Cogent Biosciences	N/A
CRMD CorMedix	34.18%
RTTR Ritter Pharmaceuticals	0.84%

Insider Ownership

Company	Insider Ownership
BCYC Bicycle Therapeutics	22.90%
COGT Cogent Biosciences	7.29%
CRMD CorMedix	5.30%
RTTR Ritter Pharmaceuticals	15.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCYC Bicycle Therapeutics	240	69.25 million	53.40 million	Optionable
COGT Cogent Biosciences	80	113.86 million	105.56 million	Optionable
CRMD CorMedix	30	67.82 million	64.23 million	Optionable
RTTR Ritter Pharmaceuticals	7	46.15 million	N/A	Not Optionable

RTTR, CRMD, COGT, and BCYC Headlines

Recent News About These Companies

Rochester football bows to St. Louis Cardinal Ritter in battle of state champions

October 4, 2024 | sj-r.com

Scott Ritter claims search of home is related to 'foreign agent’ law

August 9, 2024 | timesunion.com

FBI raids NY home of ex-UN weapons inspector Scott Ritter

August 9, 2024 | nypost.com

John Ritter Biography & Movies

May 22, 2024 | tribute.ca

Jeff Ritter

April 19, 2024 | si.com

Dr. John D. Ritter

January 24, 2024 | health.usnews.com

German chocolate war ends with Ritter Sport victory

October 28, 2023 | politico.eu

Kristen Ritter

September 15, 2023 | health.usnews.com

Op-ed column: Sandusky sex charges contrast with setup against Scott Ritter

July 8, 2023 | dailygazette.com

Scott Ritter arrested in Pennsylvania on child sex charges

July 8, 2023 | dailygazette.com

Dr. Harold K. Ritter

July 8, 2023 | health.usnews.com

Denver Business Journal welcomes new tech reporter

July 1, 2023 | bizjournals.com

Gary W. Ritter, Ph.D.

June 16, 2023 | slu.edu

Jason Ritter and Drew Barrymore's raw conversation on her show may matter more than you think

April 10, 2023 | usatoday.com

Ritter Pharmaceuticals Changing the Game With Lactose Intolerance Treatment

March 29, 2023 | thestreet.com

Global Microbiome Market Report 2023: Major Players Include MicroBiome Therapeutics, Seres Therapeutics, Enterome Bioscience and Second Genome

March 18, 2023 | finance.yahoo.com

Melanie Lynskey's husband Jason Ritter will join her in Yellowjackets this season

January 19, 2023 | yahoo.com

Ritter Public Library in Vermilion adds book club

January 15, 2023 | morningjournal.com

Microbiome Clinical Trial Pipeline Space Brims with Novel Emerging Therapies with 130+ Key Players Working in the Domain | DelveInsight

November 16, 2022 | finance.yahoo.com

Burlington freshman Olivia Ritter hits to pool as Olivia Kraus climbs out of the water

October 1, 2022 | thehawkeye.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RTTR, CRMD, COGT, and BCYC Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

$7.42 +0.01 (+0.13%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$7.27 -0.15 (-2.04%)

As of 06/20/2025 04:27 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Cogent Biosciences NASDAQ:COGT

$7.23 -0.01 (-0.14%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$7.23 0.00 (0.00%)

As of 06/20/2025 06:00 PM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

CorMedix NASDAQ:CRMD

$13.61 +0.03 (+0.22%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$13.58 -0.02 (-0.18%)

As of 06/20/2025 07:17 PM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Ritter Pharmaceuticals NASDAQ:RTTR

Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time